


PHARMACEUTICAL 2018



Edesa Biotech Inc. Rank 73 of 342





PHARMACEUTICAL 2018

Edesa Biotech

Edesa Biotech Inc. Rank 73 of 342

The relative strengths and weaknesses of Edesa Biotech Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Edesa Biotech Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 65% points. The greatest weakness of Edesa Biotech Inc. is the variable Net Income, reducing the Economic Capital Ratio by 48% points.

The company's Economic Capital Ratio, given in the ranking table, is 191%, being 146% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	6,758
Cost of Goods Sold	250
Intangible Assets	0
Liabilities, Current	321
Liabilities, Non-Current	0
Other Assets	82
Other Compr. Net Income	0
Other Expenses	285
Other Liabilities	0
Other Net Income	195
Other Revenues	228
Property and Equipment	880
Research and Development	1,973
Selling, General and Administrative Expense	2,945

Output Variable	Value in 1000 USD
Assets	7,720
Liabilities	321
Expenses	5,454
Revenues	228
Stockholders Equity	7,399
Net Income	-5,031
Comprehensive Net Income	-5,031
Economic Capital Ratio	191%

